Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review.
Chen-Yi YangYing-Ren ChenHuang-Tz OuShihchen KuoPublished in: Cardiovascular diabetology (2021)
Using GLP-1RAs versus insulin for type 2 diabetes patients requiring intensified injection therapy in clinical practice is cost-effective.
Keyphrases
- type diabetes
- glycemic control
- systematic review
- clinical practice
- end stage renal disease
- ejection fraction
- insulin resistance
- newly diagnosed
- meta analyses
- chronic kidney disease
- prognostic factors
- randomized controlled trial
- stem cells
- ultrasound guided
- weight loss
- mesenchymal stem cells
- patient reported
- smoking cessation